Partnering News: Roche, Bayer & MoreBy
A roundup of bio/pharmaceutical partnering news from Roche/Jemincare, and Bayer/BioCardia.
Roche, Jemincare In $650-M Deal for Prostate Cancer Drug
Roche, through its subsidiary Genentech, and Shanghai Jemincare Pharmaceutical, a subsidiary of the bio/pharmaceutical company, Jiangxi Jemincare, have entered into an exclusive worldwide license agreement for the development and commercialization of Jemincare’s prostate cancer drug candidate, JMKX002992, in a deal worth up to $650 million ($60 million upfront and $590 million in milestone payments).
JMKX002992 is a small-molecule oral degrader of the androgen receptor, considered a driver in prostate cancer.
Under the agreement, Genentech will be granted an exclusive license to develop and commercialize the drug worldwide and will be fully responsible for the development and commercialization costs. In return, Genentech will pay Jemincare $60 million upfront, and Jemincare is also entitled to receive up to $590 million in additional payments upon achievement of certain development, regulatory, and sales-based milestone targets. Jemincare is also entitled to receive tiered royalties on net sales.
Bayer’s BlueRock Therapeutics, BioCardia Partner in Cell-Therapy Delivery
BioCardia, a Sunnyvale, California-based bio/pharmaceutical company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has entered into an agreement with Bayer’s BlueRock Therapeutics for the delivery of BlueRock’s cell-therapy product candidates for heart failure using BioCardia’s biotherapeutic delivery product candidates.
Under the terms of the agreement, BioCardia will receive an up-front payment, which was not disclosed, a portion of which is creditable for biotherapeutic delivery products and support services. The agreement has an option to negotiate for a non-exclusive worldwide license to BioCardia biotherapeutic delivery product candidates for certain cell types for cardiac indications and is time limited.